top of page

About us

Creating new therapies for neurodegenerative disorders

Our management team encompasses diverse backgrounds and expertise, all united by a shared commitment to enhancing the quality of life for individuals affected by neurodegenerative disorders.

Our story

CEREBRO Therapeutics was founded in 2022 by three professors at Laval University, situated in beautiful Quebec city, Canada.

​

Our focus is to bring our gene therapy approach against Parkinson’s disease closer to the clinic. We also believe our strategy could be used to treat other neurodegenerative disorders like Alzheimer’s disease. Moreover, we are always looking for new ways to deliver antibodies and other small molecules to the brain for an effective treatment of neurodegenerative diseases.

Our team

Martin Levesque_edited.png

Martin Lévesque, Ph.D.

Co-founder and president

Dr. Lévesque has extensive expertise in animal and cell models of Parkinson's, and his research focuses on the development new therapeutic approaches for neurodegenerative disorders.

gravel_claude_-_cropped_0_edited.jpg

Claude Gravel, Ph.D.

Co-founder and vice-president

Dr. Gravel is a pioneer in the use of viral vectors for the treatment of devastating degenerative disorders, including retinal degeneration, amyotrophic lateral sclerosis and Parkinson's disease.

HUSSEIN_Samer_fond_blanc.jpg

Samer Hussein, Ph.D.

Co-founder and executive vice president

Dr. Hussein is an expert in the use of embryonic and induced pluripotent stem cell-based models, as well as neural differentiation, and human 3D cerebral organoids. 

Annamarie-1_edited.jpg

Anne-Marie Castonguay, Ph.D.

Operations manager

Dr. Castonguay has expertise in the development and in vivo testing of gene- and immunotherapy approaches for Parkinson's disease. Her role is to support the growth of the company and coordinate everyday operations.

bottom of page